e-learning
resources
Paris 2018
Tuesday, 18.09.2018
Drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons
E. Gurbanova (Tartu, Estonia), R. Mehdiyev (Baku, Azerbaijan), K. Blöndal (Reykjavik, Iceland), A. Altraja (Tartu, Estonia)
Source:
International Congress 2018 – Drug-resistant tuberculosis
Session:
Drug-resistant tuberculosis
Session type:
Poster Discussion
Number:
3680
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Gurbanova (Tartu, Estonia), R. Mehdiyev (Baku, Azerbaijan), K. Blöndal (Reykjavik, Iceland), A. Altraja (Tartu, Estonia). Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons. 3680
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Spreading of resistance to group A anti-tuberculosis drugs among TB patients in Astana city
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
New and repurposed drugs for MDR-TB patients
Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence
Year: 2017
MDR-TB and XDR-TB: drug resistance and treatment outcomes
Source: Eur Respir J 2009; 34: 778
Year: 2009
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
Source: Eur Respir J 2013; 42: 156-168
Year: 2013
Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs
Source: Eur Respir J 2002; 20: Suppl. 38, 614s
Year: 2002
Resistance to second-line antituberculous drugs of
Mtb
strains in TB institute clinic
Source: Eur Respir J 2007; 30: Suppl. 51, 442s
Year: 2007
Antituberculous drug resistance rates in soldier patients newly diagnosed with TB in Turkey
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Novel drug regimens against MDR-TB
Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis
Year: 2016
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
Source: ERJ Open Res, 5 (2) 00046-2019; 10.1183/23120541.00046-2019
Year: 2019
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Antituberculosis drug resistance rates in patients newly diagnosed with TB in Istanbul
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Year: 2012
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Investigating trends in antituberculosis (anti-TB) drug resistance among treated patients of a university respiratory infections unit in Greece
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept